Phio Pharmaceuticals Corp... (PHIO)
1.21
-0.02 (-1.63%)
At close: Apr 02, 2025, 3:59 PM
-1.63% (1D)
| Bid | 1.2 |
| Market Cap | 5.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -9.75 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | 0.07 |
| Analyst | Buy |
| Ask | 1.37 |
| Volume | 76,593 |
| Avg. Volume (20D) | 6,288,303 |
| Open | 1.26 |
| Previous Close | 1.23 |
| Day's Range | 1.20 - 1.26 |
| 52-Week Range | 1.20 - 9.79 |
| Beta | 1.27 |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...
Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 8
Stock Exchange NASDAQ
Ticker Symbol PHIO
Website https://www.phiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 230.58% from the latest price.
Stock Forecasts2 months ago
-25.7%
Phio Pharmaceuticals shares are trading lower afte...
Unlock content with
Pro Subscription
2 months ago
-45.76%
Phio Pharmaceuticals shares are trading lower after the company announced a $3.19 million registered direct offering.
